Pemphigus vulgaris is an autoimmune blistering disorder that involves the skin and mucous membranes. Few reports have described nasal and oropharyngolaryngeal lesions in pemphigus vulgaris using an endoscopic ororhinolaryngologic examination. We retrospectively reviewed the clinical records of 11 patients with pemphigus vulgaris between 2001 and 2013 with respect to their symptoms, lesion sites, lesion features, and treatments received. All patients had undergone an endoscopic ororhinolaryngologic examination. Their mucosa-related symptoms were sore throat, oral pain, odynophagia, gingival bleeding, hoarseness, and epistaxis. The most frequent sites were the oral cavity (gingiva and buccal mucosa), larynx (epiglottis and vocal fold), oropharynx (soft palate), and nasal cavity (nasal septum). Lesions were typically characterized by erosion, erosion with a whitish exudate, and erythematous patches. Thus, our study findings reveal that pemphigus vulgaris involves both the nasal and oropharyngolaryngeal regions. Patients with pemphigus vulgaris should undergo an endoscopic ororhinolaryngologic examination to determine the range of their lesions.
Introduction
Pemphigus vulgaris is an autoimmune blistering disorder that involves the skin and mucous membranes. Desmosomes form the adhesive core of intercellular junctions, which consist of desmosomal cadherins, desmogleins (Dsgs), and desmocollins (figure 1). Desmosome function is disrupted by autoantibodies (Abs), resulting in acantholysis of keratinocytes in the epidermis. The currently known target antigens are desmoglein 1 (Dsg1), desmoglein 3 (Dsg3), and plakin protein, which act as adhesion molecules between keratinocytes in the epidermis. [1] [2] [3] Pemphigus vulgaris is one of several disorders that can cause intractable oral or pharyngolaryngeal lesions. It is subclassified into mucosal-dominant and mucocutaneous-dominant types. 1, 4 The mucosal-dominant type exhibits predominantly oral erosions, 5 to 6 limited scattered skin lesions, and isolated erosion, or blisters that are ≤5 cm in diameter, whereas the mucocutaneous-dominant type exhibits extensive skin lesions in addition to oral lesions. 4 Patients with mucosal-dominant pemphigus vulgaris are usually negative for anti-Dsg1 Ab and positive for anti-Dsg3 Ab, whereas those with mucocutaneous-dominant pemphigus vulgaris are usually positive for both anti-Dsg 1 and 3 Abs.
Few reports have described these nasal and oropharyngolaryngeal lesions based on endoscopic ororhinolaryngologic examinations. Therefore, in the present study we investigated the clinical features of mucous membrane lesions in the nasal and oropharyngolaryngeal regions of patients with pemphigus vulgaris.
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Visit us at COSM Booth #605 Tissue samples that were obtained by biopsy were examined by routine histologic examinations, including hematoxylin and eosin staining and direct immunofluorescence examination. Tissue biopsies of the oral cavity or pharynx were obtained for 7 of 11 patients and from the skin for 4 of 11 patients.
A diagnosis was made based on clinical findings, histologic findings (i.e., suprabasal acantholysis), di-rect immunofluorescence, or immunohistochemical microscopic examination, and the presence of indirect anti-Dsg1 and/or anti-Dsg3 Abs. The mucosal-dominant type exhibits predominantly oral erosions, 5 to 6 limited scattered skin lesions, and isolated erosion, or blisters that are ≤5 cm in diameter. The mucocutaneous-dominant type exhibits extensive skin lesions in addition to oral lesions. 4 The sites and features of the lesions on the nasal cavity and oropharyngolarynx are described. Results of laboratory tests are expressed as means ± standard deviations.
This study was approved by the local ethics committee and was conducted in accordance with the ethical standards established in the Helsinki Declaration of 1975 (as revised in 1983). Informed consent was obtained from all patients at the time of their follow-up examinations.
Results
Clinical findings. The diagnosis, the patients were aged 28 to 91 years (mean: 58.9 years). Symptom durations were from 2 days to 15 months (mean: 105 days; median: 1 month).
Patients' symptoms at presentation included sore throat (7/11, 64%), oral pain (4/11, 36%), odynophagia (3/11, 27%), gingival bleeding (1/11, 9%), hoarseness (1/11, 9%), epistaxis (1/11, 9%), and rash (3/11, 27%).
The sites of membranous lesions included the oral cavity, oropharynx, hypopharynx, larynx, and nasal cavity (figure 2, table). The most frequent sites of membrane lesions included the gingiva, buccal mucosa, soft palate, epiglottis, vocal fold, and nasal septum (table) .
The membranous lesions were typically characterized by erosion, erosion with a whitish exudate, and erythematous patches. Only 5 of the 11 patients had skin lesions either on the face, chest, abdomen, back, or upper and/or lower limbs (table). These skin lesions appeared erosive or eruptive. Mucous membrane lesions were observed before the skin lesions appeared for 3 patients and after the skin lesions for 2 patients. The remaining 6 patients had no skin lesions.
Laboratory test results. White blood cell counts were generally within the reference range (4,300 to 13,200 cells/μl; mean: 7,291 ± 693 cells/μl). C-reactive protein levels were 0.0 to 3.5 mg/dl (mean: 0.44 ± 0.31 mg/dl). Serum levels of diagnostic autoantibodies, anti-Dsg1 and anti-Dsg3, were also measured (cut-off indices used were: anti-Dsg1 Abs: index13; anti-Dsg3 Abs: index 6).
Anti-Dsg1 Ab levels were elevated in 5 of 11 patients (45%), whereas anti-Dsg3 Abs levels were elevated in all 11 patients (100%). Four (57%) of 7 patients with mucosal-dominant pemphigus vulgaris had elevated anti-Dsg3 Abs levels alone, whereas 3 patients (43%) had both elevated anti-Dsg1 Abs and anti-Dsg3 Abs levels. Of the 4 patients with mucocutaneous-dominant pemphigus vulgaris, 2 (50%) had both elevated anti-Dsg1 Abs and anti-Dsg3 Abs levels and 2 (50%) had an elevated anti-Dsg3 Abs level only. For 5 (45%) of 11 patients, two subtypes did not match the pemphigus vulgaris subtype predicted by the anti-Dsg Abs profile. Histopathologic findings. Tissue biopsies were obtained from oral mucosa in 6 patients, pharyngeal mucosa in 1, and skin in 4 patients. For all patients, the histopathologic findings showed a suprabasilar slit over the intact basal layer with acantholytic cells. The results of direct immunofluorescence or immunohistochemical microscopic studies for all patients were positive for deposits of immunoglobulin G (IgG) and/or C3 in the epidermal intracellular space. Figure 3 shows representative histopathologic findings of the buccal mucosa for a patient with mucosal-dominant pemphigus vulgaris. Hematoxylin and eosin staining histopathology showed a suprabasilar slit over the intact basal layer with acantholytic cells (figure 3, A), and direct immunofluorescence staining showed C3 deposition in the epidermal intracellular space ( figure 3, B) .
Treatments. All patients were treated with systemic and/or topical steroids. Nine patients were treated with oral prednisolone (20 to 60 mg). After a lesion was controlled, the prednisolone dose was tapered to <0.2 mg/kg. For 1 patient with nasal lesions, a topical steroid of a nasal spray that contained mometasone furoate hydrate was administrated at 200 μg/day, but no systemic steroid was used; subsequently, the erosive nasal lesions disappeared. For laryngeal lesions, we administered a fluticasone propionate inhalant at 200 μg/ day, which improved the vocal fold lesions. In another patient with oral lesions only, a topical steroid ointment that contained dexamethasone controlled the lesions.
Discussion
The difference between mucosal-and mucocutaneous-dominant pemphigus vulgaris is based on their phenotypes. 4 Typically, Dsg3 is the target antigen for mucosal-dominant pemphigus vulgaris, and both Dsg1 and Dsg3 for mucocutaneous-dominant pemphigus vulgaris. 1 Dsg1 and Dsg3 are distributed throughout the skin and mucosa, although they differ in their distribution pattern. 5, 6 In the skin, Dsg1 is found throughout the epidermis and is expressed more intensely in the upper layer of the epidermis, whereas Dsg3 is found in the basal and OHKI, KIKUCHI
Figure 2. Erosion with a whitish exudate (arrow) is seen on the hard palate (A). Erosive epiglottis with a whitish exudate (arrow) is shown (B). Erosion with a whitish exudate (arrow) is visible on the vocal fold (C), and erosion (asterisk) is seen on the nasal septum (D).
parabasal cell layers. In the mucosa, Dsg1 and Dsg3 are distributed in all layers, although the expression of Dsg3 is greater than that of Dsg1. The features of lesions can be explained by the desmoglein compensation theory. 1 If either Dsg 1 or Dsg3 function is disrupted because of an antibody directed against it, then Dsg1 or Dsg3 compensates for the impaired adhesive function of the other. However, when their expression in tissue is low, neither can sufficiently compensate for the other and frank tissue impairment occurs. 1 When only anti-Dsg 1 Abs are found in serum (i.e., pemphigus foliaceus), these antibodies interfere with Dsg1 function. The Dsg1 function that is interfered with in the epidermis can be compensated for by coexisting enriched expression of Dsg3 in the lower layer of the epidermis, but it cannot be compensated for by poorly expressed Dsg3 in the upper layers.
Although the function of Dsg1 that is expressed in all the layers of the mucosa is impaired by these antibodies, coexisting Dsg3, when expressed at a higher level than Dsg1, can compensate for the loss of Dsg1 function. Therefore, lesions appear only in the upper layer of the epidermis of the skin.
When only anti-Dsg 3 Abs are found in serum (i.e., mucosal-dominant pemphigus vulgaris), the function of Dsg3 that is interfered with in the epidermis can be compensated for by Dsg1 that is expressed throughout the epidermis. However, in the mucosa, Dsg1 cannot compensate for the function of Dsg3 that is interfered with because of the poor Dsg1 expression. Therefore, lesions appear in the mucosa without apparent skin lesions.
When both anti-Dsg1 Abs and anti-Dsg3 Abs are found in serum (i.e., mucocutaneous-dominant pemphigus vulgaris), then both Dsg1 and 3 functions are interfered with and cannot be compensated for by each other. Therefore, lesions appear in both the skin and mucosa. However, the subclasses differentiated by the target antigens (i.e., Dsg1 and Dsg3) were not always identical to the clinical phenotypes for 45% (5/11) of our patients.
Jamora et al reported that 40% (10/25) of patients with these two clinical phenotypes (mucosal-dominant or mucocutaneous-dominant) were mismatched with the subclass predicted by anti-Dsg Abs. 7 Zagorodniuk et al also reported that 33% (14/42) of patients were mismatched. 8 Mucosal-dominant pemphigus vulgaris sometimes exhibits slight skin lesions, and mucocutaneous-dominant pemphigus vulgaris does not always exhibit skin lesions when the first symptoms appear. Over time, skin lesions usually appear in many of these cases. 3 Because the epidermis becomes detached at the basal NASAL, ORAL, AND PHARYNGOLARYNGEAL MANIFESTATIONS OF PEMPHIGUS VULGARIS: ENDOSCOPIC ORORHINOLARYNGOLOGIC EXAMINATION and prickle cell layers, a mucosal lesion usually appears erosive and covered with a whitish exudate. When this whitish exudate peels off, the mucosal lesion then becomes eroded, with or without bleeding. The reported sites of mucosal lesions and their frequencies are the oral cavity (90 to 100%), pharynx (38 to 85%), larynx (40 to 85%), esophagus (23%), nasal cavity (11 to 76%), ear (8 to 27%), vagina (7%), and conjunctivae (4%). 5, 6, [9] [10] [11] [12] [13] [14] [15] Lesions in the oral cavity are typically observed in the buccal mucosa (71; 90%), palate (44; 60%), tongue (42; 28%), lips (35; 25%), gingiva (24; 43%), and floor of the mouth (20; 28%). 10, 15 Symptoms appear in the oral cavity (68 to 100%), pharynx (54 to 82%), larynx (38 to 44%), esophagus (14%), nasal cavity (14 to 82%), and ear (8 to 27%). 5, 6, 9, 10, 12, 13, 15 The most frequent site is the oral cavity, and approximately half of the initial symptoms are related to oral lesions. 3 During the course of this disease, oral symptoms appear in almost 100% of cases. 5 These symptoms depend on the sites of impaired desmosome function and usually vary in their presentation, such as oral pain, stinging, sore throat, hoarseness, dysphonia, dysphagia, odynophagia, epistaxis, nasal congestion, blood-tinged mucus, otalgia, ear canal obstruction, vaginal discharge and pain, ocular pain, and excessive tearing. 5, 6, [9] [10] [11] [12] [13] [14] [15] Even if lesions do appear, a patient may be asymptomatic. España et al noted that some patients were asymptomatic for pharyngeal, laryngeal, or nasal symptoms, even though active lesions were found in 5 of 16 patients (31%). 6 For patients with mucosal lesions only and without skin lesions, the diagnosis is often delayed or missed.
Data reported by Kavala et al showed that patients with lesions in the throat (pharynx and larynx) or the nasal cavity presented related symptoms at a rate of 96% (27/28) and 97% (28/29), respectively, while ear lesions were only in 25% (1/4). 9 In their series, pharyngeal lesions were observed in 66% (25/38) and pharyngeal-related symptoms were in 82% (31/38), but laryngeal lesions were in 55% (21/38) and related symptoms were in only 32% (12/38). Kavala et al concluded that pharyngeal and nasal involvement was associated with symptoms, but that laryngeal and ear involvement was not significantly associated with symptoms. 9 Patients can have demonstrable laryngeal lesions even if they do not present with laryngeal symptoms. Hale and Bystryn reported that 40% (21/53) of patients presented with laryngeal symptoms, and 57% (4/7) of patients exhibited laryngeal involvement. 14 Mahmoud et al showed that 40% (16/40) of patients had laryngeal lesions and concluded that laryngeal involvement was common in pemphigus vulgaris and must be considered during diagnosis. 11 Nasopharyngolaryngeal endoscopy or upper gastrointestinal endoscopy results often reveal pharyngolaryngeal or esopharyngeal lesions. Otorhinolaryngologists and gastroenterologists who perform these examinations must be aware of the features of the mucosal lesions in pemphigus vulgaris.
Kavala et al, 9 Fernández et al, 15 Hale and Bystryn, 14 Robati et al, 13 and Fawzy et al 12 concluded that an endoscopic ororhinolaryngologic evaluation should be performed to accurately evaluate the mucosal areas in all patients, whether with or without symptoms. However, these mucosal features (i.e., erosion with or without a white coating) are not unique to pemphigus vulgaris. They resemble the mucosal lesions of pemphigoid. Therefore, it is impossible to make a diagnosis based only on the appearance of the mucosa; diagnostic pathologic and serologic examinations are required. It is occasionally difficult to discriminate pemphigus vulgaris from common pharyngolaryngitis when at an acute stage. White blood cell counts and C-reactive protein levels are usually within their reference ranges in pemphigus vulgaris. These routine blood tests are probably useful unless a patient's condition is complicated by some other infection.
The first-line treatment is steroid administration (prednisolone, 0.5 to 1.0 mg/kg/day). For skin lesions, an antibiotic or steroid ointment is used in combination with an oral steroid. Oral and nasopharyngolaryngeal lesions generally respond to corticosteroid therapy. 13, 14 For mucosal lesions, a steroid ointment or a nasal spray may be effective. We administered fluticasone propionate as an inhalant at 200 μg/day for laryngeal lesions and mometasone furoate hydrate nasal spray at 200 μg/day for nasal lesions. Good lesion control was achieved for all our patients. Therefore, these topical steroids may be effective, safe, and useful for nasal and pharyngolaryngeal lesions.
Regarding other combination therapies, immunosuppressive therapy, plasmapheresis, and intravenous gamma globulin are sometimes used. 1 After the disease is controlled, the daily prednisolone dose should be gradually tapered to <0.2 mg/kg. Disease activity is associated with Dsg1 and Dsg3 antibody titers. 16 Thus, monitoring anti-Dsg1 Abs and anti-Dsg3 Abs levels is useful for determining disease activity and for adjusting the steroid dose.
There are some limitations to this study. We only enrolled patients who had consulted with the otolaryngology department because of nasal and/or oropharyngolaryngeal symptoms. Thus, we did not include patients without nasal and/or oropharyngolaryngeal symptoms. Therefore, our results do not reflect the frequencies of nasal and oropharyngolaryngeal lesions in the entire population of patients with pemphigus vulgaris, but only those with nasal and/or oropharyngolaryngeal symptoms. Furthermore, our number of enrolled patients was small. A larger study population will be needed to more precisely determine the rate of involvement.
Conclusion
Pemphigus vulgaris most frequently involves the oral cavity, followed by the larynx, oropharynx, and nasal cavity. Lesions appear erosive and either with or without a whitish exudate. An endoscopic ororhinolaryngologic examination is necessary to determine the ranges of these lesions.
